Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 368, Issue 6, pp 470–478

L-type Ca2+ channels activation and contraction elicited by myricetin on vascular smooth muscles

  • Fabio Fusi
  • Simona Saponara
  • Maria Frosini
  • Beatrice Gorelli
  • Giampietro Sgaragli
Original Article


The effects of myricetin (3,3’,4’,5,5’,7-hesahydroxyflavone), a natural flavonoid found in edible plants, were studied on vascular smooth muscle L-type Ca2+ channels by comparing its mechanical, radioligand binding, and electrophysiological properties to those of the Ca2+ channel agonist (S)-(-)-Bay K 8644.

In rat aorta rings, both myricetin and (S)-(-)-Bay K 8644 induced contractile responses, which were dependent upon prior exposure to K+. At 15 mM K+ (K15) the pEC50 values for myricetin and (S)-(-)-Bay K 8644 were 4.43±0.03 and 7.92±0.13, respectively. Furthermore, the maximum tension response to myricetin was not significantly different from that elicited by either (S)-(-)-Bay K 8644 or K60. The Ca2+ channel blockers nifedipine, verapamil and diltiazem antagonised and fully reverted myricetin-, (S)-(-)-Bay K 8644- as well as K60-induced contractions. Both myricetin and (S)-(-)-Bay K 8644 potentiated rat aorta ring responses to K+, shifting the K+ concentration-response curve to the left. (S)-(-)-Bay K 8644, but not myricetin, inhibited in a concentration-dependent manner (+)-[3H]PN200–110 binding in porcine aortic membranes. Electrophysiological recordings from single rat tail artery myocytes, under amphotericin B-perforated as well as conventional methods, showed that both myricetin and (S)-(-)-Bay K 8644 increased L-type Ba2+ current (IBa(L)) and shifted the maximum of the current-voltage relationship by 10 mV in the hyperpolarising direction, without, however, modifying the threshold potential. Furthermore, (S)-(-)-Bay K 8644 accelerated both activation and inactivation kinetics of IBa(L) while myricetin slowed down the activation kinetics. Finally, both (S)-(-)-Bay K 8644 and myricetin slowed down deactivation kinetics of IBa(L).

These results suggest that myricetin induces vasoconstriction by activating L-type Ca2+ channel with similar efficacy but a site of action different to that of (S)-(-)-Bay K 8644.


(S)-(-)-Bay K 8644 Myricetin Vascular smooth muscle Whole-cell patch-clamp Wine polyphenols 



L-type Ba2+ current


Physiological salt solution


Holding potential


  1. Berger ME, Golub MS, Chang CT, al-Kharouf JA, Nyby MD, Hori M, Brickman AS, Tuck ML (1992) Flavonoid potentiation of contractile responses in rat blood vessels. J Pharmacol Exp Ther 263:78–83PubMedGoogle Scholar
  2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedGoogle Scholar
  3. Cheng YC, Prusoff WH (1973) Relationship between the inhibitory constant (Ki) and the concentrations of an inhibitor which causes 50 per cent inhibition (IC50) of an enzyme reaction. Biochem Pharmacol 22:3099–3108PubMedGoogle Scholar
  4. Duarte J, Perez-Vizcaino F, Zarzuelo A, Jimenez J, Tamargo J (1993) Vasodilator effects of quercetin in isolated rat vascular smooth muscle. Eur J Pharmacol 239:1–7CrossRefPubMedGoogle Scholar
  5. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J, Aro A (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545–553PubMedGoogle Scholar
  6. Fusi F, Marazova K, Pessina F, Gorelli B, Valoti M, Frosini M, Sgaragli GP (2000) On the mechanisms of the antispasmodic action of some hindered phenols in rat aorta rings. Eur J Pharmacol 394:109–115PubMedGoogle Scholar
  7. Fusi F, Saponara S, Gagov H, Sgaragli GP (2001) 2,5-Di-t-butyl-1,4-benzohydroquinone (BHQ) inhibits vascular L-type Ca2+ channel via superoxide anion generation. Br J Pharmacol 133:988–996PubMedGoogle Scholar
  8. Fusi F, Saponara S, Pessina F, Gorelli B, Sgaragli G (2003) Effects of quercetin and rutin on vascular preparations. A comparison between mechanical and electrophysiological phenomena. Eur J Nutr 42:10–17PubMedGoogle Scholar
  9. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41:492–499CrossRefPubMedGoogle Scholar
  10. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth J (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391:85–100PubMedGoogle Scholar
  11. Herrera MD, Zarzuelo A, Jimenez J, Marhuenda E, Duarte J (1996) Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships. Gen Pharmacol 27:273–277CrossRefPubMedGoogle Scholar
  12. Hertog MG, Feskens EJ, Kromhout D (1997) Antioxidant flavonols and coronary heart disease risk. Lancet 349:699Google Scholar
  13. Janis RA, Silver PJ, Triggle DJ (1987) Drug action and cellular calcium regulation. Adv Drug Res 16:311–591Google Scholar
  14. Jimenez R, Andriambeloson E, Duarte J, Andriantsitohaina R, Jimenez J, Perez-Vizcaino F, Zarzuelo A, Tamargo J (1999) Involvement of thromboxane A2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta. Br J Pharmacol 127:1539–1544PubMedGoogle Scholar
  15. McDonald MS, Hughes M, Burns J, Lean ME, Matthews D, Crozier A (1998) Survey of the free and conjugated myricetin and quercetin content of red wines of different geographical origins. J Agric Food Chem 46:368–375CrossRefPubMedGoogle Scholar
  16. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751PubMedGoogle Scholar
  17. Munson PJ, Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239PubMedGoogle Scholar
  18. National Institute of Health (1985) Guide for the Care and Use of Laboratory Animals. National Institute of Health Publications, No. 85-23, revised edition. National Institute of Health, Bethesda, MDGoogle Scholar
  19. Paganga G, Rice-Evans CA (1997) The identification of flavonoids as glycosides in human plasma. FEBS Lett 401:78–82CrossRefPubMedGoogle Scholar
  20. Rae J, Cooper K, Gates P, Watsky M (1991) Low access resistance perforated patch recordings using amphotericin B. J Neurosci Methods 37:15–26PubMedGoogle Scholar
  21. Saponara S, Sgaragli GP, Fusi F (2002) Quercetin as a novel activator of L-type Ca2+ channels in rat tail artery smooth muscle cells. Br J Pharmacol 135:1819–1827PubMedGoogle Scholar
  22. Su CM, Swamy VC, Triggle DJ (1984) Calcium channel activation in vascular smooth muscle by BAY K 8644. Can J Physiol Pharmacol 62:1401–1410PubMedGoogle Scholar
  23. Usowicz MM, Gigg M, Jones LM, Cheung CW, Hartley SA (1995) Allosteric interactions at L-type calcium channels between FPL 64176 and the enantiomers of the dihydropyridine Bay K 8644. J Pharmacol Exp Ther 275:638–645PubMedGoogle Scholar
  24. Wei XY, Luchowski EM, Rutledge A, Su CM, Triggle DJ (1986) Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle. J Pharmacol Exp Ther 239:144–153PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Fabio Fusi
    • 1
  • Simona Saponara
    • 1
  • Maria Frosini
    • 1
  • Beatrice Gorelli
    • 1
  • Giampietro Sgaragli
    • 1
  1. 1.Dipartimento di Scienze Anatomiche e BiomedicheUniversità degli Studi di SienaSienaItaly

Personalised recommendations